Closing the RCT Gap-A Large Meta-Analysis on the Role of Surgery in Stage I-III Small Cell Lung Cancer Patients

Area of Science:

• Oncology
• Thoracic Surgery
• Evidence-Based Medicine

Background:

• Surgery is recommended for stage I small cell lung cancer (SCLC) but is inconsistently applied.
• The role of surgery in stages II and III SCLC remains controversial.
• Current evidence relies on observational data due to a lack of randomized control trials (RCTs).

Purpose of the Study:

• To compare the efficacy of surgical versus non-surgical treatment in patients with stage I to III SCLC.
• To evaluate the impact of surgery on survival rates in SCLC patients.

Main Methods:

• A systematic review and meta-analysis of studies published up to July 1, 2023.
• Included 10 original studies with a total of 95,323 patients.
• Assessed study quality using the ROBINS-I tool and analyzed data according to PRISMA standards.

Main Results:

• The meta-analysis included 95,323 patients from 10 studies, with no indication of publication bias.
• Five-year survival rates were significantly higher in the surgery group (39.6%) compared to the non-surgery group (16.7%) for stages I-III SCLC (p < 0.0001).
• Patients in stages II and III who received surgery outside guidelines showed improved 5-year survival (36.3%) versus non-surgery controls (20.2%; p = 0.043).

Conclusions:

• This meta-analysis suggests surgery significantly improves survival for all stages of SCLC.
• Non-surgical approaches may lead to reduced survival times.
• Surgical evaluation should be considered for all non-metastatic SCLC patients as part of multimodal therapy.